Found 285 articles for: "biologics"
Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis
August 2019 | Volume 18 | Issue 8 | Original Article | 790 | Copyright © August 2019
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with l...
Read MorePrescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database
August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019
Introduction: Selecting a systemic therapy for patients with psoriasis is a complex process, based on a variety of factors including psoriasis severity, comorbid health conditions, ac...
Read MoreCombination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry
August 2019 | Volume 18 | Issue 8 | Original Article | 731 | Copyright © August 2019
Importance: There are increasing options for systemic combination therapy for psoriasis but a lack of literature around the characteristics of patients who are started on these regime...
Read MoreClinical Pathologic Mismatch in a TNF-α Inhibitor-Associated Drug Reaction
August 2019 | Volume 18 | Issue 8 | Case Reports | 218 | Copyright © August 2019
A 56-year-old Caucasian male with a history of chronic plaque psoriasis, primary sclerosing cholangitis status-post liver transplant on tacrolimus, and ulcerative colitis on infliximab developed a pro...
Read MoreGrover’s Disease Treated With Total Skin Electron Beam Radiotherapy
April 2019 | Volume 18 | Issue 4 | Case Reports | 392 | Copyright © April 2019
Persistent Grover's disease can cause significant symptoms of pruritus thereby decreasing quality of life. Many patients undergo successful conservative management of their disease; however, a subset...
Read MoreTreatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
April 2019 | Volume 18 | Issue 4 | Original Article | 387 | Copyright © April 2019
INTRODUCTION: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have b...
Read MoreOnset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update
March 2019 | Volume 18 | Issue 3 | Original Article | 229 | Copyright © March 2019
Objectives: The time that drugs for moderate-to-severe psoriasis take to see a clinically meaningful improvement (TOA) is one of the most important attributes of treatment success. This study synth...
Read MoreApremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
February 2019 | Volume 18 | Issue 2 | Original Article | 170 | Copyright © February 2019
BACKGROUND: Treatment options are limited for patients with hidradenitis suppurativa (HS). Apremilast, an oral phosphodiesterase 4 inhibitor, may offer an attractive therapeutic option for patients wi...
Read MoreSystemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice
February 2019 | Volume 18 | Issue 2 | Original Article | 122 | Copyright © February 2019
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects around 13% of children and 7% of adults in the US. It can have a significant impact on the quality of life (QoL) of affected ...
Read MoreIncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A
January 2019 | Volume 18 | Issue 1 | Original Article | 52 | Copyright © January 2019
Aesthetic dermatologic applications of botulinum neurotoxin (BoNT), including treatment of glabellar lines, horizontal forehead lines, and crow’s feet, were the most common non-surgical cosmetic pro...
Read MoreNavigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules
December 2018 | Volume 17 | Issue 12 | Features | 1330 | Copyright © December 2018
Dermatology is entering an exciting era with new, targeted immune-modulating medications for treating a variety of dermatologic conditions including psoriasis, atopic dermatitis (AD), and hidradenitis...
Read MoreGastrointestinal Signs and Symptoms Related to Inflammatory Bowel Disease in Patients With Moderate-to-Severe Psoriasis
December 2018 | Volume 17 | Issue 12 | Original Article | 1298 | Copyright © December 2018
BACKGROUND: Psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with comorbidities, including inflammatory bowel disease (IBD), given common immunopathogenic mechanisms. Whe...
Read MoreHalobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis
December 2018 | Volume 17 | Issue 12 | Original Article | 1290 | Copyright © December 2018
BACKGROUND: A unique fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion has been shown to be effective in psoriasis using Investigator Global Assessment (IGA) tools t...
Read MoreAdverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
November 2018 | Volume 17 | Issue 11 | Original Article | 1211 | Copyright © November 2018
OBJECTIVE: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/t...
Read MoreOpen-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
October 2018 | Volume 17 | Issue 10 | Original Article | 1078 | Copyright © October 2018
INTRODUCTION: Response to etanercept therapy in patients who have failed apremilast therapy has not been well characterized. METHODS: In this multicenter, open-label, single-arm, phase 4, estimatio...
Read MoreSafety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
October 2018 | Volume 17 | Issue 10 | Original Article | 1062 | Copyright © October 2018
BACKGROUND: Topical corticosteroids (TCS) are the mainstay of psoriasis treatment; long-term safety concerns limiting con...
Read MoreWhat Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab
August 2018 | Volume 17 | Issue 8 | Supplement Individual Articles | 29 | Copyright © August 2018
Brodalumab, a fully human antibody of the interleukin-17 receptor, is highly effective in the treatment of moderate-to-severe plaque psoriasis. However, based on safety signals identified in clinical ...
Read MoreDepression? It's the Disease NOT the Drug
August 2018 | Volume 17 | Issue 8 | Supplement Individual Articles | 28 | Copyright © August 2018
Research into the immunopathological mechanisms of plaque psoriasis has produced increasingly targeted biologic therapies. The specificity of these agents allows for high rates of efficacy and decreas...
Read MoreTreat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy
August 2018 | Volume 17 | Issue 8 | Editorials | 918 | Copyright © August 2018
Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements
August 2018 | Volume 17 | Issue 8 | Original Article | 886 | Copyright © August 2018
Introduction: Despite a growing arsenal of therapies for psoriasis and, consequently, an increasing number of advertisements for these treatments, many psoriasis patients still remain untreated. While...
Read More